Reconciled ClinicalTrials.gov v2 Protocol Specification
| Protocol Field | Verified Registry Value |
|---|---|
| NCT Identifier | NCT05479994 |
| Consolidated Lead Sponsor | BeiGene |
| Therapeutic Condition Cohort | Oncology and Hematology |
| Clinical Trial Phase | Phase II |
| Overall Recruitment Status | ACTIVE NOT RECRUITING |
| Registered Enrollment | 100 participants (ACTUAL) |
| Registered Start Date | 2022-10-25 |
| WhyStopped Classification | Not Stopped |
Named U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Site Profile |
|---|---|---|
| Peking University Third Hospital | Beijing, China | Open Hospital Dossier -> |
| Beijing Hospital | Beijing, China | Open Hospital Dossier -> |
| Fujian Cancer Hospital | Fuzhou, China | Open Hospital Dossier -> |
| Lanzhou University Second Hospital | Lanzhou, China | Open Hospital Dossier -> |
Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.